SEC Form 4 · accession 0001193125-26-321085
Fulgent Genetics, Inc. · FLGT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hanlin Gao
Officer — Chief Scientific Officer
Period of report
Jul 26, 2026
Accepted (ET)
Jul 28, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001674930
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 26, 2026 | F | 1,645 | $19.67 | D | 988,729 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.